Copenhagen Prospective Personalized Oncology (CoPPO)-Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials.
Ida Viller TuxenKristoffer Staal RohrbergOlga OestrupLise Barlebo AhlbornAne Yde SchmidtIben SpanggaardJane P HasselbyEric Santoni-RugiuChristina Westmose YdeMorten Mau-SørensenFinn Cilius NielsenUlrik LassenPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)
Our study supports the feasibility of genomic profiling to select patients in the phase I setting and suggests that genomic matching can be beneficial for a minor subset of patients with no other treatment options. Randomized studies may validate this assumption.See related commentary by Ratain, p. 1136.